Vectalys

Vectalys is a biotech startup founded in 2005 by Pascale Bouillé, specializing in gene delivery through lentiviral vectors. With a dedicated team of 25 full-time employees, Vectalys provides lentiviral vectors, cell models, molecular biology strategies, and project support to scientists globally. The company's advanced proprietary technology ensures top-quality lentiviral vectors, enabling efficient transduction of challenging cells like primary cells, stem cells, and in vivo tissues. Vectalys offers 100% transduction efficiency and non-toxic transduction across various target cells, making it ideal for creating predictive models. The company also customizes lentiviral vectors for specific applications and genes of interest. Additionally, Vectalys manufactures highly pure, ready-to-use lentiviral vectors carrying fluorescent, bioluminescent, or gene-editing proteins for global distribution, saving time and supporting ambitious scientific projects. The startup raised €1.50M in its last Venture Round investment on 13 June 2017 with Auriga Partners as the investor. Vectalys is pioneering excellence in gene delivery to empower groundbreaking scientific discovery and therapeutic development worldwide within the industries of biotechnology, health and wellness, and manufacturing.